Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
IGF2BP2 CRISPR/Cas9 KO Plasmid (m): sc-435664
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IGF2BP2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the IGF2BP2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IGF2BP2 CRISPR/Cas9 KO Plasmid (m) | sc-435664 | 20 µg | $397.00 |
Overview
Igf2bp2 encodes IGF2BP2, an RNA-binding protein that recognizes N6-methyladenosine (m6A)-modified transcripts and modulates mRNA stability, localization, and translation. Through post-transcriptional control of gene expression, IGF2BP2 influences metabolic signaling networks including insulin/IGF and PI3K–AKT pathways, thereby affecting cellular growth, energy homeostasis, and stress responses. In mouse models and human genetics, altered IGF2BP2 activity has been linked to metabolic phenotypes such as insulin resistance and type 2 diabetes susceptibility, and dysregulated expression is also reported across proliferative and inflammatory contexts. These features make IGF2BP2 a useful node for studying RNA fate decisions and m6A-dependent regulation in metabolic and disease-relevant cell states.
IGF2BP2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Igf2bp2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Igf2bp2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Igf2bp2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish IGF2BP2 protein expression.
This CRISPR knockout system enables efficient generation of Igf2bp2-deficient cell models for investigation of IGF2BP2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Igf2bp2 exon(s) critical for IGF2BP2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Igf2bp2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by IGF2BP2 CRISPR/Cas9 KO Plasmid (m) and IGF2BP2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Igf2bp2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by IGF2BP2 HDR Plasmid (m) and IGF2BP2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Igf2bp2 homology arms to support homology-directed repair at defined Igf2bp2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.